Bolsas y Mercados Españoles
Company
search
PHARMA MAR, S.A.
AddressAV/ DE LOS REYES 1, 28770 COLMENAR VIEJO-MADRID 
Listed Capital11,012,944.20 Euros



PHARMA MAR
ISINES0169501022 TickerPHM Nominal0.60 MarketContinuous Market Admitted Capital11,012,944.20 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
06/12/2022Close69.280069.8800-0.8669.280069.940069.100069.472851,8893,604,874.86
05/12/2022Close69.880069.36000.7569.880069.940069.020069.605152,1793,631,921.96
X
06/12/2022 17:37:18
BidAsk
OrdersVolumePricePriceVolumeOrders
12669.120069.2800291
Data Delayed 15 minutes.

Last pay
TypeEx-datePayment DateConcept
Dividend13/07/202215/07/2022Interim 2021

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
22/07/20201 x 12

Last capital increase
PeriodProportionType
02/06/20172 x 1,000Premium


 2022
until 5/12
2021202020192018
Capitalisation *
(thousands of euros)
1,282,6411,046,5971,303,198794,858242,688
Shares
(x 1,000)
18,35518,35518,355222,649222,649
Period Close Price
(euros)
69.880057.020071.000042.840013.0800
Period Last Price
(euros)
69.880057.020071.000042.840013.0800
Period High Price
(euros)
78.3000120.0000148.000046.152033.1440
Period Low Price
(euros)
46.500052.140030.000012.936010.4520
Volume
(thousands of shares)
17,05028,27462,49726,78618,457
Turnover
(thousands of euros)
1,059,3142,399,1624,893,224650,774348,611

Profile

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.
PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).

Source: Issuing company.
06/12/2022 00:02:10

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2022